second to North America in terms of pharmaceutical sales,2 Europe dominates the world pharmaceutical manufacturing sector. For instance, 11 EU countries and Switzerland together account for over 70% of the world exports of medicinal and pharmaceutical products, and medicaments.3 About half of the world largest cosmetics companies are located in Western-Europe,4 the largest by sales being France-based l'Oreal with 22.5 billion euros of sales in 2012. Moreover, through its extensive ex situ network of botanical gardens, culture collections and gene banks, Europe hosts a considerable amount of the world genetic material, be it endemic or non-endemic. Together with Switzerland and Norway, the EU member states approximately host a quarter of all botanical gardens worldwide,5 which keep over 50% of the world living plant accessions. 6 In more than 500 culture collections and gene banks, these countries also possess 30% of all cultures of microorganisms7 and between 10 and 15% of the total accessions of germplasm for food and agriculture in the world. 8 More specifically, while not necessarily mentioned in this book, numerous examples of European research and development activities involving genetic resources and traditional knowledge can be found in the literature. Among many others, examples include:
• The development of Vernonia Galamnensis, the oil of which is used in plastic formation and coating, by the British company Vernique Biotech;9 • The development of new tomato genotypes through the European EU-SOL project, by the Dutch breeding companies Enza Zaden B.V. (higher-yielding
